News

The FDA has accepted for priority review Regeneron Pharmaceuticals’ supplemental biologics license application for aflibercept (Eylea) injection, a treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

Ophthalmology Times is pleased to announce Evan Warner, MD, of the University of Wisconsin, as the third-place winner of the publication’s 2014 Resident Writer’s Award Program, sponsored by Allergan. Dr. Warner’s submission is featured here.

A foldable, hydrophobic acrylic IOL embedded with a small-aperture mask provided excellent visual acuity across all distances in patients who underwent monocular implantation after cataract surgery and was not associated with any visual symptoms that may occur with other presbyopia-correcting IOLs.

Manufacturers of ophthalmic diagnostic systems are increasingly incorporating advances that improve the predictability of outcomes and integrate technologies.

A prospective, randomized trial of treatment for diabetic macular edema finds similar vision improvement with intravitreal bevacizumab (Avastin, Genentech) and an intravitreal dexamethasone implant (Ozurdex, Allergan), but differences in other endpoints.

For retinal surgery, the latest generation of instrumentation is anticipated to be accompanied by markedly improved fluidics, precision, and faster patient recovery.

Developments in lasers, along with genetic engineering, are showing promise as technologies that may shape the future of retina treatment.

Much of the developments in pharmacologic therapy for retina disease revolved around age-related macular degeneration and diabetic macular edema in 2014.

Specialists in glaucoma anticipate the future availability of a novel triple-action agent, as well as other medical and surgical management developments.

In terms of medication use in cataract surgery, ophthalmologists discussed the continued increasing use of the intracameral route for antibiotic administration to prevent endophthalmitis and the launch of the “Go Dropless” campaign.

Finding value in the diversity of ophthalmology is at the core of the Ophthalmic Women Leaders’ success, share two members of its Board of Directors.

Innovations in femtosecond laser-assisted cataract surgery and microinvasive glaucoma surgery continue to drive the momentum of cataract procedures into 2015.

An investigational device for diabetic retinopathy screening has a low technical failure rate, completes testing in a few minutes, provides immediate results, and is not associated with adverse events.

Clinic life really can be summed up quite nicely using famous movie quotes.

Features of a proprietary femtosecond laser system enable successful laser-assisted cataract surgery in eyes with a history of LASIK or other pre-existing corneal conditions. The addition of intraoperative aberrometry optimizes IOL power selection.

The acquisition of corneal topographic values saw an advancement this year via Scheimpflug imaging.

A retinal surgeon describes a new scleral buckling device which requires less surgical dissection, has a one or two-stitch fixation, is applicable to treat pathology over 4 clock hours in any quadrant, and which can be removed in the office 3 to 4 weeks after insertion.

An examination of the advancements made in drug therapy this past year includes ocular surface therapy, the approval of an anti-inflammatory mydriatic agent, and several dry eye drugs.

With a wide array of IOL options available to their foreign colleagues, U.S. ophthalmologists eagerly await the approval and availability of additional lenses.

Taking a look at the improvements made this past year in refractive accuracy through several new technologic evolutions.

Politicians rarely tell the truth, so why should ophthalmologists . . . right?

Not all orbital fractures need to be repaired, and not all fractures need to be repaired early after the patient sustains an insult. However, early repair of orbital factures can be beneficial for some patients. Ferreting out who those patients involves some special consideration.

Findings evaluating the incidence of posterior vitreous detachment on quality of vision and reading speed have been released.

A proof-of-concept trial was launched to determine the safety and efficacy of squalamine lactate ophthalmic solution in eyes with macular edema secondary to branch and central retinal vein occlusion.

Using the most recent nomogram for intrastromal astigmatic keratotomy using a proprietary femtosecond laser platform, the mean vector magnitude achieved was 87%.

A look at how crosslinking applications, topography-guided ablations, along with the introduction of the Symfony lens, dominated refractive surgery this past year.

Iridex has been awarded a competitive tender for more than $350,000 in ophthalmology laser equipment by the government of Zambia.

NASA has struggled to understand why many astronauts, upon returning from space missions, have experienced moderate to severe eye problems and changes to their vision, said Dorit Donoviel, PhD.

Valeant Pharmaceuticals International has acquired Nicox S.A.’s U.S. diagnostics subsidiary, Nicox, Inc., in a deal worth up to $20 million.

This collection of documents demonstrates the love and admiration that these distinguished individuals, all of whom are highly respected in the history of ophthalmology, have held for one another.